secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115077
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q3 net loss $34.1M; Phase 2 CANYON data on track for Dec 2024
----------------------------------------------------------------------

- Net loss $34.1M ($0.36 per share) vs $31.5M ($0.34) prior quarter; cash $492.5M.
- R&D expenses $32.2M (up $1.5M QoQ); G&A $8.2M (up $0.8M QoQ).
- Top-line CANYON (Becker) data expected December 2024; EDG-7500 28-day data Q1 2025.
- CIRRUS-HCM single dose: 67% mean reduction in resting LVOT gradient; no meaningful LVEF change.
- LYNX (Duchenne) data due Q4 2024; FOX trial over-enrolled within two months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924115077/0001104659-24-115077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924115077/tm2427437d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer